NCT00568022 - A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Breast Cancer

Interventions

DRUG

Ixabepilone

Ixabepilone: Intravenous (IV) Solution, IV, 32(40)mg/m\^2, once every 3 weeks, up to 6 cycles

DRUG

Capecitabine

Capecitabine: Tablets, Oral, 1650(2000)mg/m\^2, twice daily for 2 weeks, one week off, up to 6 cycles

Trial Locations (4)

Local Institution, Matsuyama

Local Institution, Maebashi

Local Institution, Osaka

Local Institution, Sunto-Gun